Cancer cells can survive and acquire drug resistance by altering the expression and/or activation profiles of survival signaling pathways, including mitogen activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK)1/2 and Akt [25, 26]. This evidence concerns the gene WNK2 and cancer.